NDC-11 (Package) (Descending) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
72903-0853-01 | 72903-0853 | Mirvetuximab soravtansine | ELAHERE | 100.0 mg/20mL | Immunotherapy | Drug Antibody Conjugate | FR-alpha, DM4 | Intravenous | Nov. 14, 2022 | In Use | |
72893-0015-24 | 72893-0015 | Dexamethasone | Hemady | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | June 11, 2020 | In Use | |
72893-0015-06 | 72893-0015 | Dexamethasone | Hemady | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | June 11, 2020 | In Use | |
72893-0006-01 | 72893-0006 | Levoleucovorin | KHAPZORY | 300.0 mg/6mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Jan. 2, 2019 | Oct. 31, 2023 | No Longer Used |
72893-0004-01 | 72893-0004 | Levoleucovorin | KHAPZORY | 175.0 mg/3.5mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Jan. 2, 2019 | In Use | |
72865-0140-90 | 72865-0140 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | March 9, 2020 | In Use | |
72865-0140-30 | 72865-0140 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | March 9, 2020 | In Use | |
72851-0042-01 | 72851-0042 | Leuprolide | CAMCEVI | 42.0 mg/mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Dec. 30, 2022 | In Use | ||
72819-0186-03 | 72819-0186 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 1, 2022 | In Use | |
72819-0185-09 | 72819-0185 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 1, 2022 | In Use |
Found 10,000 results in 3 milliseconds — Export these results